Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
JENLOGA vs ADQUEY
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
JENLOGA is a combination of sulfamethoxazole, a sulfonamide, and trimethoprim, a dihydrofolate reductase inhibitor. Sulfamethoxazole inhibits bacterial dihydrofolic acid synthesis by competing with para-aminobenzoic acid, while trimethoprim inhibits dihydrofolate reductase, blocking the conversion of dihydrofolic acid to tetrahydrofolic acid. This sequential blockade produces synergistic bactericidal activity.
ADQUEY (aducanumab) is a human monoclonal antibody that selectively targets aggregated forms of amyloid beta (Aβ), including soluble oligomers and insoluble fibrils, reducing Aβ plaques in the brain. The exact mechanism linking Aβ reduction to clinical improvement is not fully established.
Treatment of urinary tract infections due to susceptible strains of Escherichia coli, Klebsiella species, Enterobacter species, Morganella morganii, Proteus mirabilis, and Proteus vulgaris,Treatment of acute otitis media in children,Treatment of acute exacerbations of chronic bronchitis in adults,Treatment of enteritis caused by Shigella flexneri or Shigella sonnei,Prophylaxis and treatment of Pneumocystis jirovecii pneumonia,Treatment of traveler's diarrhea,Treatment of toxoplasmosis
Alzheimer disease (FDA approved for treatment of mild cognitive impairment or mild dementia stage),Off-label: none established
350 mg orally once daily with food.
400 mg orally once daily with food.
Terminal half-life 6-8 hours in healthy adults; prolonged to 12-15 hours in moderate renal impairment (Cr Cl 30-50 m L/min)
Terminal half-life 12-15 hours; prolonged in renal impairment (up to 30 hours in Cr Cl <30 m L/min)
Sulfamethoxazole is primarily metabolized via N-acetylation (N-acetyltransferase 2) and glucuronidation. Trimethoprim is metabolized primarily by oxidative O-demethylation (CYP3A4, CYP1A2) and conjugation.
Metabolized via catabolic pathways similar to endogenous Ig G; no specific cytochrome P450 enzyme involvement.
Renal (80% as unchanged drug), biliary/fecal (15% as metabolites and unchanged drug)
Renal: 70-80% unchanged; Fecal: 5-10% as metabolites; Biliary: minimal (<2%)
98% bound primarily to albumin
98% bound to albumin
0.15-0.3 L/kg, indicating limited extravascular distribution
0.2-0.3 L/kg; indicates limited extravascular distribution
Oral: 92% (high first-pass metabolism; extensive absorption)
Oral: 85-90%; IM: 95-100%
GFR ≥45 m L/min: no adjustment; GFR 30-44 m L/min: 350 mg every other day; GFR <30 m L/min or ESRD: not recommended.
Cr Cl ≥60 m L/min: no adjustment; Cr Cl 30-59 m L/min: 200 mg daily; Cr Cl <30 m L/min: 100 mg daily; hemodialysis: 100 mg daily after dialysis.
Child-Pugh A: no adjustment; Child-Pugh B: 200 mg once daily; Child-Pugh C: not recommended.
Child-Pugh A: no adjustment; Child-Pugh B: 200 mg daily; Child-Pugh C: not recommended.
Not recommended for pediatric patients due to lack of safety and efficacy data.
Weight ≥10 kg: 12 mg/kg/dose twice daily; weight <10 kg: 8 mg/kg/dose twice daily.
No specific dose adjustment recommended; monitor renal function closely in patients ≥65 years.
Initial dose 200 mg daily; titrate based on renal function; monitor for neuropsychiatric effects.
Fatal hypersensitivity reactions including Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, agranulocytosis, aplastic anemia, and other blood dyscrasias have been reported with sulfonamides. JENLOGA is contraindicated in patients with a history of hypersensitivity to sulfonamides or trimethoprim.
Amyloid-related imaging abnormalities (ARIA), including ARIA-E (edema/effusion) and ARIA-H (hemosiderin deposition), can occur. ARIA is usually asymptomatic but serious events including seizure and status epilepticus have been reported. Patients with apolipoprotein E ε4 homozygosity have a higher incidence of ARIA.
Fatal hypersensitivity reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis); discontinue at first sign of rash,Hematologic toxicity including agranulocytosis, aplastic anemia; monitor CBC regularly,Hepatic necrosis; discontinue if signs of liver injury occur,Severe renal impairment (Cr Cl <15 m L/min); avoid use,Potential for hyperkalemia in patients with renal dysfunction or those on potassium-sparing diuretics,Risk of folate deficiency; monitor folate levels in chronic therapy,Photosensitivity; avoid prolonged sun exposure
1) Amyloid-related imaging abnormalities (ARIA): monitor with MRI before and during treatment; consider dose interruption or discontinuation if severe. 2) Hypersensitivity reactions: angioedema, urticaria reported. 3) Risk of falls due to cognitive impairment. 4) No head-to-head trials showing superiority over other treatments.
Hypersensitivity to sulfonamides or trimethoprim,History of drug-induced immune thrombocytopenia with prior sulfonamides,Megaloblastic anemia due to folate deficiency,Severe renal impairment (Cr Cl <15 m L/min) unless for Pneumocystis jirovecii pneumonia treatment,Pregnancy at term and nursing mothers (due to potential for kernicterus in neonates),Concomitant use with dofetilide (increases risk of arrhythmias)
History of severe hypersensitivity to aducanumab or any excipients in ADQUEY.
Take with or without food. High-fat meals may delay absorption but no significant clinical impact. Avoid grapefruit and grapefruit juice as they may alter drug levels.
Avoid grapefruit and grapefruit juice; may increase drug levels. High-fat meals can increase absorption; take with food or on an empty stomach consistently.
Pregnancy exposure registry data indicate increased risk of major congenital malformations, including neural tube defects, cardiovascular anomalies, and cleft palate, with first-trimester exposure. Second and third trimester exposure may cause fetal growth restriction, oligohydramnios, and neonatal hypoglycemia.
ADQUEY (estradiol valerate/dienogest) is contraindicated in pregnancy. First trimester exposure may cause congenital anomalies including cardiovascular and neural tube defects. Second and third trimester exposure may lead to feminization of male fetuses and other adverse outcomes.
Not recommended during breastfeeding. M/P ratio not established; drug is excreted in human milk. Potential for serious adverse reactions in nursing infants.
Excretion into breast milk is minimal; however, ADQUEY may reduce milk production and quality. M/P ratio not established. Avoid use during breastfeeding.
Dose adjustments required due to increased volume of distribution and enhanced clearance; monitor trough levels and adjust to maintain therapeutic range. Consider 30-50% dose increase in third trimester.
Contraindicated in pregnancy; no dose adjustments applicable. Discontinue immediately if pregnancy occurs.
Jenloga (cenobamate) is a tetrazole-derived antiepileptic drug. Titrate slowly to reduce risk of severe hypersensitivity reactions, including DRESS syndrome. Monitor for QT shortening on ECG. Dose adjustments needed in renal impairment. Consider lower starting dose in patients with hepatic impairment.
Administration with a full glass of water and staying upright for 30 minutes reduces risk of esophagitis. Monitor for cutaneous lupus erythematosus and Stevens-Johnson syndrome. Avoid concomitant use with drugs that prolong QT interval due to risk of torsades de pointes.
Take exactly as prescribed; do not stop suddenly without medical advice.,Report any rash, fever, or swollen lymph nodes immediately.,Avoid alcohol and other CNS depressants.,Use effective contraception; drug may cause fetal harm.,Notify healthcare provider if you become pregnant or plan to.,May cause dizziness or somnolence; avoid driving until effects known.
Take exactly as prescribed; do not double doses if missed.,Swallow tablet whole; do not crush or chew.,Avoid direct sunlight; use sunscreen and protective clothing.,Report any skin rash, blisters, or eye irritation immediately.,Do not take with antacids, iron supplements, or sucralfate; separate by at least 4 hours.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about JENLOGA vs ADQUEY, answered by our medical review team.
JENLOGA is a Oral Contraceptive that works by JENLOGA is a combination of sulfamethoxazole, a sulfonamide, and trimethoprim, a dihydrofolate reductase inhibitor. Sulfamethoxazole inhibits bacterial dihydrofolic acid synthesis by competing with para-aminobenzoic acid, while trimethoprim inhibits dihydrofolate reductase, blocking the conversion of dihydrofolic acid to tetrahydrofolic acid. This sequential blockade produces synergistic bactericidal activity.. ADQUEY is a Oral Contraceptive that works by ADQUEY (aducanumab) is a human monoclonal antibody that selectively targets aggregated forms of amyloid beta (Aβ), including soluble oligomers and insoluble fibrils, reducing Aβ plaques in the brain. The exact mechanism linking Aβ reduction to clinical improvement is not fully established.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between JENLOGA and ADQUEY depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of JENLOGA is: 350 mg orally once daily with food.. The standard adult dose of ADQUEY is: 400 mg orally once daily with food.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between JENLOGA and ADQUEY in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. JENLOGA is classified as Category C. Pregnancy exposure registry data indicate increased risk of major congenital malformations, including neural tube defects, cardiovascular anomalies, and cleft palate, with first-tr. ADQUEY is classified as Category C. ADQUEY (estradiol valerate/dienogest) is contraindicated in pregnancy. First trimester exposure may cause congenital anomalies including cardiovascular and neural tube defects. Sec. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.